Optomed Oyj Third Quarter 2024 Earnings: Revenues Disappoint

Optomed Oyj (HEL:OPTOMED) Third Quarter 2024 Results

Key Financial Results

• Revenue: €3.11m (down 26% from 3Q 2023).
• Net loss: €1.58m (loss widened by 259% from 3Q 2023).
• €0.087 loss per share (further deteriorated from €0.027 loss in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Optomed Oyj Earnings Insights

Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Medical Equipment industry in Finland.

Performance of the Finnish Medical Equipment industry.

The company's shares are up 15% from a week ago.

Risk Analysis

It is worth noting though that we have found 4 warning signs for Optomed Oyj (1 shouldn't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.